- Scheme Category:
- Equity Scheme >
- Sectoral/Thematic Funds
NAV: ₹ ↓ -0.79%
NAV chart
SMA (Simple Moving Average)
- 50 SMA
- 100 SMA
- 200 SMA
- 400 SMA
Returns
CAGR returns till date
CAGR returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option and its peers as on 13 February, 2026| Name | YTD | 1D | 1W | 1M | 3M | 1Y | 3Y | 5Y | 7Y | 10Y |
|---|---|---|---|---|---|---|---|---|---|---|
| Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option | -1.21% | -0.79% | 1.3% | -0.97% | -2.66% | 6.75% | 23.43% | 15.68% | 19.88% | 15.39% |
| SBI CONSUMPTION OPPORTUNITIES FUND - DIRECT PLAN - GROWTH | -3.44% | -1.05% | 0.6% | -1.55% | -4.72% | 1.29% | 13.92% | 16.69% | 16.2% | 16.86% |
| SBI ESG Exclusionary Strategy Fund - Direct Plan -Growth | -1.92% | -0.96% | -0.17% | -0.93% | -1.11% | 10.24% | 14.69% | 12.18% | 14.56% | 14.93% |
| SBI HEALTHCARE OPPORTUNITIES FUND - DIRECT PLAN -GROWTH | -0.71% | -1.01% | 1.53% | -0.77% | -3.47% | 3.79% | 25.54% | 16.87% | 21.41% | 13.46% |
| SBI INFRASTRUCTURE FUND - DIRECT PLAN - GROWTH | -1.43% | -1.21% | -0.35% | 1.76% | -1.33% | 8.93% | 22.39% | 21.1% | 21.08% | 18.32% |
| SBI PSU Fund - DIRECT PLAN - GROWTH | 5.59% | -1.19% | 1.43% | 5.81% | 6.15% | 30.1% | 35.14% | 29.88% | 23.35% | 18.01% |
Discrete returns (yearly)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Returns | -9.42% | 8.09% | 4.71% | 2.97% | 68.53% | 23.84% | -9.16% | 41.33% | 35.46% | -2.94% |
Discrete returns (monthly)
| Month | Apr 2025 | May 2025 | Jun 2025 | Jul 2025 | Aug 2025 | Sep 2025 | Oct 2025 | Nov 2025 | Dec 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Returns | 4.91% | 1.43% | 3% | 2.66% | -1.41% | -2.52% | 2.24% | 0.9% | -1.24% | -4.66% |
Returns from spefic dates
| Description | CAGR returns from 18 Oct 2021 (Nifty 50 2021 high) | CAGR returns from 26 Sep 2024 (Nifty 50 2024 high) |
|---|---|---|
| Returns | 12.81% | -1.69% |
Portfolio
Asset allocation
| Equity | Debt | Realestate | Commodities | Cash & Equivalents |
|---|---|---|---|---|
| 99.67% | 0.00% (Arbitrage: 0.00%) | 0.00% | 0.00% | 0.33% |
Equity
| Name | Symbol / ISIN | Sector | Weight % |
|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA (INE044A01036) | Pharmaceuticals & Biotechnology | 12.67% |
| Divi's Laboratories Limited | DIVISLAB (INE361B01024) | Pharmaceuticals & Biotechnology | 8.07% |
| Lupin Limited | LUPIN (INE326A01037) | Pharmaceuticals & Biotechnology | 7.26% |
| Cipla Limited | CIPLA (INE059A01026) | Pharmaceuticals & Biotechnology | 6.29% |
| Apollo Hospitals Enterprise Limited | APOLLOHOSP (INE437A01024) | Healthcare Services | 5.97% |
| Dr. Reddy's Laboratories Limited | DRREDDY (INE089A01031) | Pharmaceuticals & Biotechnology | 5.62% |
| Vijaya Diagnostic Centre Limited | VIJAYA (INE043W01024) | Healthcare Services | 3.42% |
| MedPlus Health Services Limited | MEDPLUS (INE804L01022) | Retailing | 3.32% |
| Gland Pharma Limited | GLAND (INE068V01023) | Pharmaceuticals & Biotechnology | 3.05% |
| GlaxoSmithKline Pharmaceuticals Limited | GLAXO (INE159A01016) | Pharmaceuticals & Biotechnology | 2.87% |
| Ajanta Pharma Limited | AJANTPHARM (INE031B01049) | Pharmaceuticals & Biotechnology | 2.83% |
| Sai Life Sciences Limited | SAILIFE (INE570L01029) | Pharmaceuticals & Biotechnology | 2.81% |
| Thyrocare Technologies Limited | THYROCARE (INE594H01019) | Healthcare Services | 2.59% |
| Abbott India Limited | ABBOTINDIA (INE358A01014) | Pharmaceuticals & Biotechnology | 2.39% |
| Aurobindo Pharma Limited | AUROPHARMA (INE406A01037) | Pharmaceuticals & Biotechnology | 2.32% |
| Dr. Lal Path Labs Limited | LALPATHLAB (INE600L01024) | Healthcare Services | 2.29% |
| Mankind Pharma Limited | MANKIND (INE634S01028) | Pharmaceuticals & Biotechnology | 2.16% |
| Alkem Laboratories Limited | ALKEM (INE540L01014) | Pharmaceuticals & Biotechnology | 2.14% |
| Biocon Limited | BIOCON (INE376G01013) | Pharmaceuticals & Biotechnology | 2.10% |
| JB Chemicals & Pharmaceuticals Limited | JBCHEPHARM (INE572A01036) | Pharmaceuticals & Biotechnology | 2.01% |
| Pfizer Limited | PFIZER (INE182A01018) | Pharmaceuticals & Biotechnology | 1.99% |
| Narayana Hrudayalaya Limited | NH (INE410P01011) | Healthcare Services | 1.95% |
| IPCA Laboratories Limited | IPCALAB (INE571A01038) | Pharmaceuticals & Biotechnology | 1.50% |
| Suraksha Diagnostic Limited | SURAKSHA (INE877V01027) | Healthcare Services | 1.48% |
| Fortis Healthcare Limited | FORTIS (INE061F01013) | Healthcare Services | 1.35% |
| Sanofi India Limited | SANOFI (INE058A01010) | Pharmaceuticals & Biotechnology | 1.32% |
| Sanofi Consumer Healthcare India Limited | SANOFICONR (INE0UOS01011) | Pharmaceuticals & Biotechnology | 1.24% |
| Max Healthcare Institute Limited | MAXHEALTH (INE027H01010) | Healthcare Services | 1.23% |
| Syngene International Limited | SYNGENE (INE398R01022) | Healthcare Services | 1.00% |
| Anthem Biosciences Limited | ANTHEM (INE0CZ201020) | Pharmaceuticals & Biotechnology | 0.90% |
| Akums Drugs and Pharmaceuticals Limited | AKUMS (INE09XN01023) | Pharmaceuticals & Biotechnology | 0.84% |
| Emcure Pharmaceuticals Limited | EMCURE (INE168P01015) | Pharmaceuticals & Biotechnology | 0.74% |
| AstraZeneca Pharma India Limited | ASTRAZEN (INE203A01020) | Pharmaceuticals & Biotechnology | 0.72% |
| Indoco Remedies Limited | INDOCO (INE873D01024) | Pharmaceuticals & Biotechnology | 0.61% |
| Orchid Pharma Limited | ORCHPHARMA (INE191A01027) | Pharmaceuticals & Biotechnology | 0.43% |
| Concord Biotech Limited | CONCORDBIO (INE338H01029) | Pharmaceuticals & Biotechnology | 0.19% |
Portfolio data is as on date 31 October, 2025
NAV history
Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option - 30 days NAV (Net asset value) history
| Date | NAV |
|---|---|
| 13 February, 2026 | 562.6333 |
| 12 February, 2026 | 567.1247 |
| 11 February, 2026 | 570.6492 |
| 10 February, 2026 | 565.0555 |
| 9 February, 2026 | 562.4167 |
| 6 February, 2026 | 555.4307 |
| 5 February, 2026 | 556.3385 |
| 4 February, 2026 | 555.8449 |
| 3 February, 2026 | 557.7097 |
| 2 February, 2026 | 542.9962 |
| 30 January, 2026 | 545.5001 |
| 29 January, 2026 | 539.2707 |
| 28 January, 2026 | 545.2017 |
| 27 January, 2026 | 544.1395 |
| 23 January, 2026 | 543.9098 |
| 22 January, 2026 | 550.6493 |
| 21 January, 2026 | 544.7383 |
| 20 January, 2026 | 546.5968 |
| 19 January, 2026 | 556.0414 |
| 16 January, 2026 | 560.1734 |
| 14 January, 2026 | 566.4457 |
| 13 January, 2026 | 568.1619 |
| 12 January, 2026 | 568.6731 |
| 9 January, 2026 | 570.5985 |
| 8 January, 2026 | 574.5657 |
| 7 January, 2026 | 582.5272 |
| 6 January, 2026 | 580.1143 |
| 5 January, 2026 | 572.6209 |
| 2 January, 2026 | 572.9644 |
| 1 January, 2026 | 569.5079 |
FAQ (Frequently asked questions)
What is latest/current NAV/price of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The latest NAV of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option is 562.6333 as on 13 February, 2026.What are YTD (year to date) returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The YTD (year to date) returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are -1.21% as on 13 February, 2026.What are 1 year returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The 1 year returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 6.75% as on 13 February, 2026.What are 3 year CAGR returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The 3 year annualized returns (CAGR) of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 23.43% as on 13 February, 2026.What are 5 year CAGR returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The 5 year annualized returns (CAGR) of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 15.68% as on 13 February, 2026.What are 10 year CAGR returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The 10 year annualized returns (CAGR) of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 15.68% as on 13 February, 2026.